ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0743

Home-Based Telehealth in Rheumatology: A Systematic Review & Narrative Synthesis

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 1028

How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0666

HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0786

Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 0753

Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0785

Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 0983

Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0815

Hyper-IgG4 in Patients with Systemic Autoinflammatory Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0923

Identification of Cell-Specific DNA Methylation Changes Associated with MTX Treatment Response in Rheumatoid Arthritis

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0638

Identification of New Candidate Drugs for SLE Using a Drug Repurposing Transcriptomic Approach on Blood, Skin and Kidney Samples from 3439 Patients

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 1087

Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 0761

Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0594

Identification of Peptidylglycine Alpha-Amidating Monooxygenase as a Regulator of Tissue Damage Mediated by Rheumatoid Arthritis Synovial Fibroblasts

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0633

Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0907

Identifying Trajectories of Remission in Patients with Rheumatoid Arthritis Treated in a Tertiary Care Centre

RA – Diagnosis, Manifestations, and Outcomes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].